Press releaseGlobe Newswire
Metagenomi Therapeutics
MGX · NASDAQ
$0.8313+$0.0195 (+2.40%)TodayMarket closed ·
Prev close $0.8118
About MGX
- Employees
- 119
- Headquarters
- Emeryville, California
- Listed
- Feb 9, 2024
- Sector
- Health Care
- Industry
- Biotechnology
- Website
- metagenomi.co
MGX key statistics
- Market cap
- 31.40M
- Price-earnings ratio
- 0.00
- Dividend yield
- —
- Average volume
- 173.67K
- Volume
- 94.11K
- Open price
- $0.8225
- High today
- $0.8566
- Low today
- $0.80
- 52 Week high
- $3.40
- 52 Week low
- $0.769
Metagenomi Therapeutics (MGX) at a glance
As of Oct 20, 2026, Metagenomi Therapeutics (MGX) shares are priced at $0.8313, giving the company a market cap of 31.40M and a price-to-earnings ratio of 0.00.
Today the stock has traded between $0.80 and $0.8566. The current price is 3.9% above the day's low and 3.0% below its high.
Volume so far is 94.11K shares, below the average of 173.67K shares a day.
Over the past year Metagenomi Therapeutics has ranged from $0.769 to $3.40, and now sits 2% of the way up that range.
Metagenomi Therapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.73 per share against an estimate of -$0.5767.
The average analyst price target is $7.14, 758.9% above the current price, from 2 recent ratings.
Analyst ratings
Latest rating from each analyst over the past 12 months
100%of 2 analyst ratings say Buy
- Buy100.0%
- Hold0.0%
- Sell0.0%
Price target · 4 analystsAvg $7.14
- Low
- $5.05
- Now
- $0.8313
- High
- $9.45
MGX earnings
Earnings per share, reported against the analyst estimate
Beat the estimate in 5 of the last 8 quarters, by 14.9% on average.
- Q3 FY24: reported -$0.51 per share against an estimate of -$0.7835
- Q4 FY24: reported -$0.63 per share against an estimate of -$0.7575
- Q1 FY25: reported -$0.68 per share against an estimate of -$0.5838
- Q2 FY25: reported -$0.54 per share against an estimate of -$0.6272
- Q3 FY25: reported -$0.55 per share against an estimate of -$0.5898
- Q4 FY25: reported -$0.60 per share against an estimate of -$0.6115
- Q1 FY26: reported -$0.61 per share against an estimate of -$0.5319
- Q2 FY26: reported -$0.73 per share against an estimate of -$0.5767
MGX news
- Press releaseGlobe Newswire
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
- Press releasePRNewswire
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
- Press releasePRNewswire
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
- Press releaseGlobe Newswire
Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference
- Press releasePRNewswire
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
- Press releaseGlobe Newswire
Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference
12 Health Care Stocks Moving In Wednesday's Intraday Session
Similar companies
Companies in the same industry as Metagenomi Therapeutics
Most active stocks
Highest trading volume today
- EARIEntertainment Arts Research$0.0003−16.67%
- SEIISharing Economy International$0.0004+100.00%
- NWGLCL Workshop Group$0.1522+27.90%
- TMSHTrans Global Assets$0.0002+0.00%
- AEFIAmerican EcoFuels$0.0007+0.00%
- CBDW1606$0.0002+0.00%
- FITYFifty 1 Labs$0.0001−66.67%
- PRSOPeraso$0.5914+54.13%
- SDSTStardust Power$0.02−23.66%
- SHFSSHF Holdings$0.0899−4.36%
- FRTTFort Technology$0.7121+32.63%
- CBDLCBD Life Sciences$0.0002−25.00%
Newly listed
Companies that went public in the past six weeks
- TCXBTCGX Acquisition Corp. II$10.56+1.54%
- CTYCITY THERAPEUTICS$20.83−2.94%
- IAMIambic Therapeutics$16.01−2.02%
- AMROAmaero$5.68+1.25%
- FLSCFrazier Life Sciences Acquisition Corp. II$10.28−0.10%
- TRXBTRex Bio$14.44−2.43%
- RTSNRetension Pharmaceuticals$16.18−0.92%
- PAXGUPine Tree Acquisition$9.98+0.00%
- PORTUSouthport Acquisition Corp. IIListed Oct 1, 2026
- CHWMChilwa Minerals$5.18+3.39%
- ACCVAccelevation Holdings$12.31−1.44%
- RZAIROZE AI$10.28+1.28%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.